SCM
LGND icon

Suvretta Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Suvretta Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-123,774
Closed -$7.36M – 117
2020
Q3 		$7.36M Buy
+123,774
New +$8.45M 0.13% 59

Other funds holding LGND

William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Suvretta Capital Management's LGND Position: Q4 2020 in Review

Suvretta Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2020, closing a stake of 123,774 shares — an estimated $7.36M sold.

Suvretta Capital Management first reported a position in LGND in Q3 2020 and held it in 1 quarter. The position peaked at $7.36M in Q3 2020. 242 funds tracked by Wall St. Rank hold LGND as of Q4 2020.

  • Suvretta Capital Management reported no remaining Ligand Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Suvretta Capital Management sold 123,774 Ligand Pharmaceuticals shares in Q4 2020, an estimated $7.36M.
  • Suvretta Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Suvretta Capital Management's Ligand Pharmaceuticals position peaked at $7.36M in Q3 2020.
  • 242 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2020.

Based on Suvretta Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.